18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders. Preclinically, 18F-PI-2620 binds to both 3-repeat and 4-repeat tau isoforms. The purpose of this first-in-humans study was to evaluate the ability of 18F-PI-2620 to detect tau pathology in AD patients using PET imaging, as well as to assess the safety and tolerability of this new tau PET tracer. Methods: Participants with a clinical diagnosis of probable AD and healthy controls (HCs) underwent dynamic 18F-PI-2620 PET imaging for 180 min. 18F-PI-2620 binding was assessed visually and quantitatively using distribution volume ratios (DVR) estimated from noninvasive tracer kinetics and SUV ratio (SUVR) measured at different time points after injection, with the cerebellar cortex as the reference region. Time-activity curves and SUVR were assessed in AD and HC subjects, as well as DVR and SUVR correlations and effect size (Cohen's d) over time. Results: 18F-PI-2620 showed peak brain uptake around 5 min after injection and fast washout from nontarget regions. In AD subjects, focal asymmetric uptake was evident in temporal and parietal lobes, precuneus, and posterior cingulate cortex. DVR and SUVR in these regions were significantly higher in AD subjects than in HCs. Very low background signal was observed in HCs. 18F-PI-2620 administration was safe and well tolerated. SUVR time-activity curves in most regions and subjects achieved a secular equilibrium after 40 min after injection. A strong correlation (R 2 > 0.93) was found between noninvasive DVR and SUVR for all imaging windows starting at more than 30 min after injection. Similar effect sizes between AD and HC groups were obtained across the different imaging windows. 18F-PI-2620 uptake in neocortical regions significantly correlated with the degree of cognitive impairment. Conclusion: Initial clinical data obtained in AD and HC subjects demonstrated a high image quality and excellent signal-to-noise ratio of 18F-PI-2620 PET for imaging tau deposition in AD subjects. Noninvasive quantification using DVR and SUVR for 30-min imaging windows between 30 and 90 min after injection-for example, 45-75 min-provides robust and significant discrimination between AD and HC subjects. 18F-PI-2620 uptake in expected regions correlates strongly with neurocognitive performance.
18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders. Preclinically, 18F-PI-2620 binds to both 3-repeat and 4-repeat tau isoforms. The purpose of this first-in-humans study was to evaluate the ability of 18F-PI-2620 to detect tau pathology in AD patients using PET imaging, as well as to assess the safety and tolerability of this new tau PET tracer. Methods: Participants with a clinical diagnosis of probable AD and healthy controls (HCs) underwent dynamic 18F-PI-2620 PET imaging for 180 min. 18F-PI-2620 binding was assessed visually and quantitatively using distribution volume ratios (DVR) estimated from noninvasive tracer kinetics and SUV ratio (SUVR) measured at different time points after injection, with the cerebellar cortex as the reference region. Time-activity curves and SUVR were assessed in AD and HC subjects, as well as DVR and SUVR correlations and effect size (Cohen's d) over time. Results: 18F-PI-2620 showed peak brain uptake around 5 min after injection and fast washout from nontarget regions. In AD subjects, focal asymmetric uptake was evident in temporal and parietal lobes, precuneus, and posterior cingulate cortex. DVR and SUVR in these regions were significantly higher in AD subjects than in HCs. Very low background signal was observed in HCs. 18F-PI-2620 administration was safe and well tolerated. SUVR time-activity curves in most regions and subjects achieved a secular equilibrium after 40 min after injection. A strong correlation (R 2 > 0.93) was found between noninvasive DVR and SUVR for all imaging windows starting at more than 30 min after injection. Similar effect sizes between AD and HC groups were obtained across the different imaging windows. 18F-PI-2620 uptake in neocortical regions significantly correlated with the degree of cognitive impairment. Conclusion: Initial clinical data obtained in AD and HC subjects demonstrated a high image quality and excellent signal-to-noise ratio of 18F-PI-2620 PET for imaging tau deposition in AD subjects. Noninvasive quantification using DVR and SUVR for 30-min imaging windows between 30 and 90 min after injection-for example, 45-75 min-provides robust and significant discrimination between AD and HC subjects. 18F-PI-2620 uptake in expected regions correlates strongly with neurocognitive performance.
Authors: Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer Journal: Alzheimers Dement Date: 2015-03-28 Impact factor: 21.566
Authors: Craig Curtis; Jose E Gamez; Upinder Singh; Carl H Sadowsky; Teresa Villena; Marwan N Sabbagh; Thomas G Beach; Ranjan Duara; Adam S Fleisher; Kirk A Frey; Zuzana Walker; Arvinder Hunjan; Clive Holmes; Yavir M Escovar; Carla X Vera; Marc E Agronin; Joel Ross; Andrea Bozoki; Mary Akinola; Jiong Shi; Rik Vandenberghe; Milos D Ikonomovic; Paul F Sherwin; Igor D Grachev; Gillian Farrar; Adrian P L Smith; Christopher J Buckley; Richard McLain; Stephen Salloway Journal: JAMA Neurol Date: 2015-03 Impact factor: 18.302
Authors: William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun Journal: Alzheimers Dement Date: 2014-10-28 Impact factor: 21.566
Authors: Marta Marquié; Marc D Normandin; Charles R Vanderburg; Isabel M Costantino; Elizabeth A Bien; Lisa G Rycyna; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik L Debnath; Neil Vasdev; Bradford C Dickerson; Stephen N Gomperts; John H Growdon; Keith A Johnson; Matthew P Frosch; Bradley T Hyman; Teresa Gómez-Isla Journal: Ann Neurol Date: 2015-09-25 Impact factor: 10.422
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Clifford R Jack; Heather J Wiste; Christopher G Schwarz; Val J Lowe; Matthew L Senjem; Prashanthi Vemuri; Stephen D Weigand; Terry M Therneau; Dave S Knopman; Jeffrey L Gunter; David T Jones; Jonathan Graff-Radford; Kejal Kantarci; Rosebud O Roberts; Michelle M Mielke; Mary M Machulda; Ronald C Petersen Journal: Brain Date: 2018-05-01 Impact factor: 13.501
Authors: Michael Schöll; Anne Maass; Niklas Mattsson; Nicholas J Ashton; Kaj Blennow; Henrik Zetterberg; William Jagust Journal: Mol Cell Neurosci Date: 2018-12-07 Impact factor: 4.314
Authors: Gabriel Cassinelli Petersen; Michelle Roytman; Gloria C Chiang; Yi Li; Marc L Gordon; Ana M Franceschi Journal: Curr Opin Neurol Date: 2022-04-01 Impact factor: 6.283
Authors: Marie Willroider; Sigrun Roeber; Anja K E Horn; Thomas Arzberger; Maximilian Scheifele; Gesine Respondek; Osama Sabri; Henryk Barthel; Marianne Patt; Olena Mishchenko; Andreas Schildan; André Mueller; Norman Koglin; Andrew Stephens; Johannes Levin; Günter U Höglinger; Peter Bartenstein; Jochen Herms; Matthias Brendel; Leonie Beyer Journal: Front Neurol Date: 2021-07-02 Impact factor: 4.003
Authors: Santiago Bullich; Olivier Barret; Cristian Constantinescu; Christine Sandiego; Andre Mueller; Mathias Berndt; Caroline Papin; Audrey Perrotin; Norman Koglin; Heiko Kroth; Andrea Pfeifer; Gilles Tamagnan; Jennifer Madonia; John P Seibyl; Kenneth Marek; Susan De Santi; Ludger M Dinkelborg; Andrew W Stephens Journal: J Nucl Med Date: 2019-11-11 Impact factor: 11.082